Light Mode
$0.0000 ↓ -0.0030 (-99.97%) Trading Down from the previous close of $0.0030, and at the day’s high of $0.0000
-0.00 (+0.00%) / 6M
Momentum, market sentiment, and recent alerts
AFMDQ reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -100.0%.
No alerts for AFMDQ in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.